← Leaderboards
Satyanarayana Rachagani
University Of Missouri-Columbia
$2,046,118
Attributed
$2,232,094
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $555.2K · FY2019–24$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$2,232,094 · 2
By mechanism
R01$1,860,141 · 1
R21$371,953 · 1
Top collaborators
- Saraswathi Viswanathan2 shared
Others in their field
Other Emerging Leaders on “Novel Therapeutics”
- Leonard Freedman · Leidos Biomedical Research, Inc.$263,124,404
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
Research focus
Novel TherapeuticsPharmaceutical PreparationsIn VitroNormal CellPancreatic Cancer PatientsPathogenesisFutureGrowthMalignant Neoplasm Of PancreasNeoplasm MetastasisOrganoidsPancreatic Cancer CellsPancreatic NeoplasmCancer CellCancer Cell LineDrug ResistanceGemcitabineCancer TherapyChemotherapyCytotoxic AgentMalignant NeoplasmsMouse ModelCombined Modality TherapyPlay
Grant awards (7)
Targeting tumor and its microenvironment using nanotherapeutics for pancreatic cancer$355,739
R01 · FY2024 · CA · contact PI
Targeting tumor and its microenvironment using nanotherapeutics for pancreatic cancer$381,093
R01 · FY2023 · CA · contact PI
Targeting tumor and its microenvironment using nanotherapeutics for pancreatic cancer$365,189
R01 · FY2022 · CA · contact PI
Targeting tumor and its microenvironment using nanotherapeutics for pancreatic cancer$372,280
R01 · FY2021 · CA · contact PI
Targeting tumor and its microenvironment using nanotherapeutics for pancreatic cancer$385,840
R01 · FY2020 · CA · contact PI
Altered Histidine Metabolism in Pancreatic Cancer: A Novel Metabolic Target to Enhance Gemcitabine Efficacy$169,392
R21 · FY2020 · CA
Altered Histidine Metabolism in Pancreatic Cancer: A Novel Metabolic Target to Enhance Gemcitabine Efficacy$202,561
R21 · FY2019 · CA